capecitabine has been researched along with trametinib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baron, AD; Barzi, A; Bekaii-Saab, TS; El-Khoueiry, AB; Guthrie, KA; Hochster, H; Javle, M; Keogh, GP; Kim, EJ; Kim, RD; McDonough, S; Sahai, V; Siegel, AB; Stein, SM | 1 |
1 trial(s) available for capecitabine and trametinib
| Article | Year |
|---|---|
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Female; Fluorouracil; Humans; Male; Middle Aged; Pyridones; Pyrimidinones | 2020 |